BEIGENE LTD-ADR (BGNE) Stock Price & Overview
NASDAQ:BGNE • US07725L1026
Current stock price
The current stock price of BGNE is 184.71 USD. Today BGNE is up by 0.49%. In the past month the price decreased by -10.23%. In the past year, price increased by 11.69%.
BGNE Key Statistics
- Market Cap
- 19.666B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -49.45
- Dividend Yield
- N/A
BGNE Stock Performance
BGNE Stock Chart
BGNE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BGNE. When comparing the yearly performance of all stocks, BGNE is a bad performer in the overall market: 69.84% of all stocks are doing better.
BGNE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BGNE. Both the profitability and financial health of BGNE have multiple concerns.
BGNE Earnings
On November 12, 2024 BGNE reported an EPS of -8.28 and a revenue of 7.18B. The company missed EPS expectations (-22.81% surprise) and beat revenue expectations (0.26% surprise).
BGNE Forecast & Estimates
11 analysts have analysed BGNE and the average price target is 185.96 USD. This implies a price increase of 0.68% is expected in the next year compared to the current price of 184.71.
For the next year, analysts expect an EPS growth of 35.87% and a revenue growth 52.03% for BGNE
BGNE Groups
Sector & Classification
BGNE Financial Highlights
Over the last trailing twelve months BGNE reported a non-GAAP Earnings per Share(EPS) of -49.45. The EPS decreased by -457.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.97% | ||
| ROE | -26.99% | ||
| Debt/Equity | 0.31 |
BGNE Ownership
BGNE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.81 | 391.561B | ||
| AMGN | AMGEN INC | 15.82 | 197.434B | ||
| GILD | GILEAD SCIENCES INC | 16.34 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.86 | 118.403B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.24 | 80.021B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.94 | 42.294B | ||
| INSM | INSMED INC | N/A | 31.169B | ||
| NTRA | NATERA INC | N/A | 28.017B | ||
| BIIB | BIOGEN INC | 11.52 | 26.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 23.418B | ||
| MRNA | MODERNA INC | N/A | 21.054B | ||
| EXAS | EXACT SCIENCES CORP | 341.95 | 19.824B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.619B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BGNE
Company Profile
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Company Info
IPO: 2016-02-03
BEIGENE LTD-ADR
c/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay
George Town BEIJING KY1-1108 KY
CEO: John V. Oyler
Employees: 10000
Phone: 13459494123
BEIGENE LTD-ADR / BGNE FAQ
What does BGNE do?
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Can you provide the latest stock price for BEIGENE LTD-ADR?
The current stock price of BGNE is 184.71 USD. The price increased by 0.49% in the last trading session.
What is the dividend status of BEIGENE LTD-ADR?
BGNE does not pay a dividend.
How is the ChartMill rating for BEIGENE LTD-ADR?
BGNE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the ownership details for BGNE stock?
You can find the ownership structure of BEIGENE LTD-ADR (BGNE) on the Ownership tab.